Clinical trial · Interventional
Developmental Study on Fatigue in Cancer
NCT00034450CI-TRIAL-00000408completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
L-carnitine is a supplement (type of vitamin) that has been suggested to be decreased in patients with cancer. We will identify patients that have terminal cancer and fatigue. The purpose of this study is to determine if L-carnitine replacement improves fatigue in cancer patients with L-carnitine deficiency.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| L-carnitine | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion: * Patients with diagnosis of cancer and estimated life expectancy of less than 6 months. * Patients who have undergone antineoplastic therapy which may worsen fatigue or promote carnitine deficiency will be eligible if completed the therapy more than 90 days prior to beginning the study. Exclusion: * Uncontrolled or severe cardiovascular, pulmonary, or renal disease. * Patients with encephalopathy or psychiatric disorder sufficiently severe to impair completion of the questionnaire. * Treatment or replacement therapy with any form of carnitine less than 12 months prior to enrollment. * Known sensitivity to carnitine. * History of seizures or stroke.
References
Publications (0)
Data not yet available
No reference posted for this study.